Long-term results for Enbrel and AS

Pharmaceutical company Amgen announced long-term results for Enbrel (etanercept): after three years, they report, 59 patients in their clinical trial "experienced sustained improvement in signs and symptoms, spinal mobility and physical function." Of that 59, 46 experienced at least 20 per cent improvement, and 18 achieved partial remission. Business Week; press release (reprinted here and here).

It's interesting to see longer-term data on the new anti-TNF treatments, especially in the context of some anecdotal reports of them not working for people after a while.